DAPTOCIN
GENSENTA
Identification
- Active ingredient (INN)
- DAPTOMYCINE
- Internal code
- 13 Y 521
- Country of Origin
- Turkey
- Pharmaceutical form
- Lyophilised Powder for IV Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- flacon/15ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
is indicated for the treatment of the following infections.
- In adults and children (aged 1-17 years) with complicated skin and soft tissue infections (IcPTM).
- In adults with right heart infectious endocarditis (AID) due to Staphylococcus aureus.
It is recommended that daptomycin be used taking into account the bacterial sensitivity of the micro-organism and expert opinion.
In l'adute, daptomycin should be used in patients with bacteraemia associated with IDE or IcPTM, while in children, daptomycin should be used in patients with bacteraemia associated with IcPH or other bacteria (adute, daptomycin, or other bacteria).
Associated Conditions
General If an outbreak of infection other than an IcPTM or IDE is identified after initiation of treatment with DAPTOMYCINE ACCORD, consideration should be given to initiating another antibacterial treatment that has demonstrated its effectiveness in the treatment of this infection.
Anaphylaxis/ hypersensitivity reactions Anaphylaxis/ hypersensitivity reactions have been reported with daptomycin.
In case of an allergic reaction to DAPTOMYCINE ACCORD, it is necessary to stop its use and initiate appropriate treatment.
Clinical studies have shown that daptomycin is not effective in the treatment of pneumonia.
Therefore, DAPTOMYCINE ACCORD is not a suitable laboratory for the treatment of patients with a disease.
Mechanism of Action
The following are the characteristics of the drug: the drug resistance is a drug resistance (e.g., the drug resistance is a natural cyclic lipopeptide active only on Gram-positive bacteria. The mechanism of action involves binding (in presence of calcium ions) to the bacterial membranes of growth phase and stationary phase cells, resulting in depolarization and rapid inhibition of protein synthesis, DNA and RNA.
The result is the death of the bacterial cell with negligible cell analysis.
PK/PD relationship The daptomycin has rapidly bactericidal concentration-dependent activity vis-à-vis in vitro and in vivo Gram-positive bacteria in animal models.
The doses of 4 mg/kg and 6 mg/kg of the virus-prone bacteria administered once a day in adult humans are a reduction in the sensitivity of AUC/CMI ratios. predictives of in vivo efficacy and bactericidal activity defined with single-dose administration of the drug, including the presence of the drug in the animal models.
Adverse Effects
(e.g., abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, abstinal, absinst, absinsinst, ab.